BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O'Meara T, Marczyk M, Qing T, Yaghoobi V, Blenman K, Cole K, Pelekanou V, Rimm DL, Pusztai L. Immunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers. JCO Precis Oncol 2020;4:PO. [PMID: 32923897 DOI: 10.1200/PO.19.00350] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Yiwei Tong, Jiahui Huang, Weili Ren, Jing Yu, Xu Zhang, Zheng Wang, Jin Hong, Weiqi Gao, Jiayi Wu, Min Ji, Kunwei Shen, Xiaosong Chen. Association of tumor immune microenvironment profiling and 21-gene recurrence assay in early breast cancer patients. Eur J Med Res 2022;27:293. [PMID: 36528658 DOI: 10.1186/s40001-022-00917-3] [Reference Citation Analysis]
2 Shukla N, Naik A, Moryani K, Soni M, Shah J, Dave H. TGF-β at the crossroads of multiple prognosis in breast cancer, and beyond. Life Sci 2022;:121011. [PMID: 36179816 DOI: 10.1016/j.lfs.2022.121011] [Reference Citation Analysis]
3 Szeitz B, Pipek O, Kulka J, Szundi C, Rusz O, Tőkés T, Szász AM, Kovács KA, Pesti A, Ben Arie TB, Gángó A, Fülöp Z, Drágus E, Vári-kakas SA, Tőkés AM. Investigating the Prognostic Relevance of Tumor Immune Microenvironment and Immune Gene Assembly in Breast Carcinoma Subtypes. Cancers 2022;14:1942. [DOI: 10.3390/cancers14081942] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Park Y, Park Y, Lim S, Lim B, Kim J. Time Series Ovarian Transcriptome Analyses of the Porcine Estrous Cycle Reveals Gene Expression Changes during Steroid Metabolism and Corpus Luteum Development. Animals 2022;12:376. [DOI: 10.3390/ani12030376] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Riaz N, Burugu S, Cheng AS, Leung SCY, Gao D, Nielsen TO. Prognostic Significance of CSF-1R Expression in Early Invasive Breast Cancer. Cancers (Basel) 2021;13:5769. [PMID: 34830923 DOI: 10.3390/cancers13225769] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Wang J, Browne L, Slapetova I, Shang F, Lee K, Lynch J, Beretov J, Whan R, Graham PH, Millar EKA. Multiplexed immunofluorescence identifies high stromal CD68+PD-L1+ macrophages as a predictor of improved survival in triple negative breast cancer. Sci Rep 2021;11:21608. [PMID: 34732817 DOI: 10.1038/s41598-021-01116-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
7 Schuler LA, Murdoch FE. Endogenous and Therapeutic Estrogens: Maestro Conductors of the Microenvironment of ER+ Breast Cancers. Cancers (Basel) 2021;13:3725. [PMID: 34359625 DOI: 10.3390/cancers13153725] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Grassadonia A, Graziano V, Iezzi L, Vici P, Barba M, Pizzuti L, Cicero G, Krasniqi E, Mazzotta M, Marinelli D, Amodio A, Natoli C, Tinari N. Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting. Cells 2021;10:1685. [PMID: 34359855 DOI: 10.3390/cells10071685] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
9 Pellegrino B, Hlavata Z, Migali C, De Silva P, Aiello M, Willard-Gallo K, Musolino A, Solinas C. Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. Mol Diagn Ther 2021;25:409-24. [PMID: 33974235 DOI: 10.1007/s40291-021-00525-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Goldberg J, Pastorello RG, Vallius T, Davis J, Cui YX, Agudo J, Waks AG, Keenan T, McAllister SS, Tolaney SM, Mittendorf EA, Guerriero JL. The Immunology of Hormone Receptor Positive Breast Cancer. Front Immunol 2021;12:674192. [PMID: 34135901 DOI: 10.3389/fimmu.2021.674192] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
11 Ricketts TD, Prieto-Dominguez N, Gowda PS, Ubil E. Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes. Front Immunol 2021;12:642285. [PMID: 34025653 DOI: 10.3389/fimmu.2021.642285] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
12 Mehta AK, Kadel S, Townsend MG, Oliwa M, Guerriero JL. Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer. Front Immunol 2021;12:643771. [PMID: 33968034 DOI: 10.3389/fimmu.2021.643771] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
13 Chafe SC, Riaz N, Burugu S, Gao D, Leung SCY, Lee AF, Lee CH, Dedhar S, Nielsen TO. Granulocyte Colony Stimulating Factor Expression in Breast Cancer and Its Association with Carbonic Anhydrase IX and Immune Checkpoints. Cancers (Basel) 2021;13:1022. [PMID: 33804486 DOI: 10.3390/cancers13051022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
14 Mahoney M, Holmes FA, Cho B. Leptomeningeal metastatic hormone receptor positive, HER2 and PD-L1 negative, breast cancer responds after pembrolizumab added to abemaciclib: A case study. Current Problems in Cancer: Case Reports 2020;2:100033. [DOI: 10.1016/j.cpccr.2020.100033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Romero-Cordoba S, Tagliabue E, Triulzi T, Bianchi F. Deep Into Breast Cancer Heterogeneity to Increase Immunotherapeutic Effectiveness. JCO Precis Oncol 2020;4:1267-8. [PMID: 35050784 DOI: 10.1200/PO.20.00313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 O’meara T, Pusztai L. Reply to S. Romero-Cordoba et al. JCO Precision Oncology 2020. [DOI: 10.1200/po.20.00352] [Reference Citation Analysis]